In this issue, there are 2 excellent large retrospective studies from single centers in Groningen, The Netherlands,1 and Haifa, Israel2 of patients referred for possible bullous pemphigoid (BP). In addition, there is a nationwide population-based study from Korea evaluating the risk of BP in patients with diabetes receiving dipeptidyl peptidase 4 inhibitors (gliptins).3
Temel AB, Murrell DF. Diagnostic Criteria and Phenotypes of Pemphigoid and the Association With Gliptins. JAMA Dermatol. 2019;155(2):147–148. doi:10.1001/jamadermatol.2018.4847
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: